We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Test Accurately Detects Latent HIV

By LabMedica International staff writers
Posted on 14 Jun 2017
The ability of the human immunodeficiency virus (HIV) to lie dormant in a "reservoir" of CD4 cells has been the main obstacle to finding a cure; once a patient starts antiretroviral therapy, it becomes very important to measure the level of viremia, and whether the virus can replicate.

Most tests available for detecting the virus are not very cost effective and take a lot of time. The most widely available test at the moment is the "quantitative viral outgrowth assay" (Q-VOA), but it requires large amounts of blood, is very labor intensive, and is quite expensive and additionally, the Q-VOA may also underestimate the amount of virus left.

Scientists at the University of Pittsburgh (PA, USA) and their colleagues developed a sensitive assay that can accurately and rapidly quantify inducible, replication-competent latent HIV-1 from resting CD4+ T cells, which is essential for HIV-1 eradication studies. The developed test is called TZA and it works by detecting a gene that is turned on only when replicating HIV is present, thereby flagging the virus for technicians to quantify.

The TZA test produces results in one week compared to the two weeks needed using the Q-VOA, and at a third of the cost. The TZA test also may be useful for quantification of replication-competent HIV-1 in the pediatric population, because of its low cell requirement, as well as in the lymph nodes and tissues where the virus persists. The assay has several advantages over existing technology in that it is sensitive; requires only a small blood volume; is faster, less labor intensive, and less expensive; and can be readily adapted into a high-throughput format. Using this assay, the authors show that the size of the inducible latent HIV-1 reservoir in aviremic participants on therapy is approximately 70-fold larger than previous estimates.

Phalguni Gupta, PhD, a professor and senior author of the study, said, “Using this test, we demonstrated that asymptomatic patients on antiretroviral therapy carry a much larger HIV reservoir than previous estimates, as much as 70 times what the Q-VOA test was detecting. Because these tests have different ways to measure HIV that is capable of replicating, it is likely beneficial to have both available as scientists strive toward a cure." The study was published on May 29, 2017, in the journal Nature Medicine.

Related Links:
University of Pittsburgh


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.